Co-Chairman of China Venture Capital & Private Equity Association;
Member of the Professional Committee of FOFs for Asset Management Association of China;
Invited expert of National Development and Reform Commission(NDRC); Judge of NDRC and Ministry of Finance's Emerging Industry Venture Investment Project;
One of the earliest PE &VC professionals in China, with more than 20 years's experience.
Expert consultant for the drafting of State Council’s‘Ten Terms for China Venture Capital’ and various industry regulations Expert of various subject groups of the State Council, Ministry of Finance and Development and Reform Commission, expert of the Party School of the CPC for fund training;
Judge of several governmental funds of the Ministry of Science and Technology, Ministry of Industry and Information Technology, Beijing Municipal Government, etc.;
Served various financial institutions in Paris, London, Shanghai and Beijing, with rich practical experience in financial market .
Qin Xiaojuan Director, COO
Secretary General of China Private Equity ESG Alliance;
Over 20 years of comprehensive operation and management experience in multinational companies and private companies, especially start-up companies, keeping long-term cooperation with multiple government agencies;
Prior to CGP, served as vice president and founding member of a reputed investment bank in China;
Participated in the fundraising and investment of multiple FOFs, with a deep understanding of management and operation;fully responsible for post-investment management and investor relation.
Tian Chen Director, General Manager of Strategic Development Department
The general manager of strategic development department of CGP, responsible for the group's innovative business exploration
Twelve years of professional experience in equity investment and operation, participated in the establishment and investment of multiple funds, expanded multi-category products, and led the completion of investments in projects such as Kylinsoft, Zhongkehualian New Material, and Chipone IC;
Served in the Group's Investment Department, Institutional Department, and President's Office.
Yang Zhijun Managing Partner
Over 19 years of experience in venture capital; one of the earliest senior professionals engaged in venture capital in Chongqing,maintained a good partnership with investors and government agencies;
Served as deputy general manager for Chongqing Technology Venture Investment Guide Fund, participated in the fund’s establishment and operation; cooperated with multiple VC institutions to form a VC fund with a scale of nearly RMB 9 billion.
Chen Lizhi Managing Partner
Over 30 years of work experience in electronic information industry (of which more than 20 years in the IC industry), engaged in IC design, group-level IC business management, investment management and fund management, responsible for the management of Beijing IC Industry Fund, Shaoxing IC Fund, Beijing Small and Medium Enterprise Development Fund ;
Served for the Planning Department of China Electronic Corporation(CEC) Technology, responsible for the related business management of the group company, and participated in various M&A and reorganizations of IC businesses.
Jiang Yan Chief Sustainability Officer, Partner
Member of Fund Industry Culture Building Committee of Asset Management Association of China (AMAC), member of Green and Sustainable Investment Committee of AMAC, member of Emission Peak & Carbon Neutrality Professional Committee of Chinese Society for Environmental Sciences;
Responsible for ESG strategy system, public affairs, theoretical research, think tank and industry association etc., familiar with ESG, green investment, impact investment system construction and full process management;
Leading the establishment of Qingtong Responsible Investment Academy to promote ESG ecological construction.
PhD of Mathematics from Peking University,MBA,Head of Healthcare Investment Team;
15 years of experience in healthcare investment, with experience in China Renaissance, KPMG, Tianjin International Institute of Biomedical Research, Amdocs China and other well-known domestic and international investment banks, accounting firms and Fortune 500 companies;
Main cases: Tong Ren Tang, Tigermed, Immunotech Biopharm, Pharmaron, Jiudian Pharmaceutical, Darui Biotechnology, BrainAu.